OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$10.14
+1.60%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 839.66x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.35x
- Price / sales
- 2123.87x
- Price / cash flow
- -7.84x
Enterprise value
- Enterprise value
- $629.0M
- EV / sales
- 2134.30x
- EV / EBITDA
- -6.61x
- EV / EBIT
- -5.95x
- Market cap
- $626.0M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026